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Focal adhesion kinase (FAK) promotes anti-tumor
immune evasion. Specifically, the kinase activity of
nuclear-targeted FAK in squamous cell carcinoma
(SCC) cells drives exhaustion of CD8+ T cells and
recruitment of regulatory T cells (Tregs) in the tumor
microenvironment by regulating chemokine/cytokine
and ligand-receptor networks, including via tran-
scription of Ccl5, which is crucial. These changes
inhibit antigen-primed cytotoxic CD8+ T cell activity,
permitting growth of FAK-expressing tumors. Mech-
anistically, nuclear FAK is associated with chromatin
and exists in complex with transcription factors and
their upstream regulators that control Ccl5 expres-
sion. Furthermore, FAK’s immuno-modulatory nu-
clear activities may be specific to cancerous squa-
mous epithelial cells, as normal keratinocytes do
not have nuclear FAK. Finally, we show that a
small-molecule FAK kinase inhibitor, VS-4718, which
is currently in clinical development, also drives
depletion of Tregs and promotes a CD8+ T cell-medi-
ated anti-tumor response. Therefore, FAK inhibitors
may trigger immune-mediated tumor regression,
providing previously unrecognized therapeutic
opportunities.INTRODUCTION
First described more than a decade ago (Onizuka et al., 1999;
Shimizu et al., 1999), regulatory T cells (Tregs) have become
recognized as a core component of the immuno-suppressive ar-
mory utilized by many tumors to keep the anti-tumor activity of
antigen-primed CD8+ T cells at bay. Increased Treg numbers
has been associated with poorer survival in ovarian (Curiel160 Cell 163, 160–173, September 24, 2015 ª2015 The Authorset al., 2004), gastrointestinal (Sasada et al., 2003), and esopha-
geal (Kono et al., 2006) cancer. Indeed, the ratio of CD8+
T cells/Tregs correlates with poor prognosis, shifting the balance
from anti-tumor immunity toward tumor tolerance (Quezada
et al., 2006; Sato et al., 2005; Shah et al., 2011). Through
secreting a range of chemokines and cytokines, cancer cells
can promote the recruitment of Tregs into tumors and can also
facilitate their peripheral expansion and retention (Darrasse-
Je`ze and Podsypanina, 2013; Ondondo et al., 2013). Thus, Tregs
can act as a barrier to effective immune-based therapy aimed at
activation of a CD8+ T cell anti-tumor immune response. How-
ever, the specific signals within tumor cells that stimulate
elevated intra-tumoral Tregs, giving rise to tumor tolerance,
remain elusive.
FAK is a tyrosine kinase that regulates diverse cellular func-
tions, including adhesion, migration, invasion, polarity, prolifera-
tion, and survival (Frame et al., 2010). Using targeted gene dele-
tion in mouse skin, we have previously shown a requirement for
fak in tumor initiation and progression to malignant disease
(McLean et al., 2004). FAK is also required for mammary tumor
progression, intestinal tumorigenesis, and the androgen-inde-
pendent formation of neuroendocrine carcinoma in a mouse
model of prostate cancer (Ashton et al., 2010; Lahlou et al.,
2007; Luo et al., 2009a; Provenzano et al., 2008; Pylayeva
et al., 2009; Slack-Davis et al., 2009). Expression of FAK is
elevated in a number of tumor types (reviewed in McLean
et al., 2005), and FAK inhibitors are being developed as potential
cancer therapeutics (Roberts et al., 2008; Shapiro et al., 2014).
Many of FAK’s functions in cancer are via its role in signaling
downstream of integrins and growth factor receptors at the
plasma membrane. FAK also contains putative nuclear localiza-
tion sequences (NLS) within the F2 lobe of its FERM domain and
can localize to the nucleus upon receipt of cellular stress, where
it binds to p53 (Lim et al., 2008). However, the extent of FAK’s nu-
clear functions remains largely unknown. Here, we report a func-
tion for nuclear FAK in regulating transcription of inflammatory
cytokines and chemokines, in turn promoting an immuno-sup-
pressive, pro-tumorigenic microenvironment. This is mediated
Figure 1. Loss of FAK or FAK Kinase Activ-
ity Results in CD8+ T Cell-Dependent SCC
Tumor Clearance
(A and B) SCC FAK-WT and SCC FAK/ subcu-
taneous tumor growth in immune-deficient CD-1
nude mice (A) and immune-competent FVB
mice (B).
(C and D) SCC FAK/ (C) and SCC FAK-WT (D)
tumor growth in FVB mice treated with T-cell-
depleting antibodies.
(E)Secondary tumor re-challengewithSCCFAK/
(top) and SCC FAK-WT (middle) cells following a
pre-challenge with SCC FAK/ cells and a 7-day
tumor-free period. Subcutaneous growth of SCC
FAK-WT and SCC FAK/ tumors injected at day
28 without pre-challenge (bottom).
(F) Tumor growth in FVB mice following subcu-
taneous injection of SCC FAK-WT, SCC FAK/,
and SCC FAK-KD cells.
*p < 0.05, **p or ++p < 0.01, ****p < 0.0001; Sidak-
corrected two-way ANOVA (A and B) or Tukey-
corrected two-wayANOVA (C,versusSCCFAK/;
D, versus SCC FAK-WT; F, *, versus SCC FAK/
and +, versus SCC FAK-KD). Data are represented
as mean ± SEM; n = 5–6 tumors.by recruitment and expansion of Tregs via FAK-regulated che-
mokine/cytokine networks, and we have found an important
role for Ccl5 and TGFb2. Therefore, FAK controls the tumor envi-
ronment, and suppressing FAK activity, including via a clinically
relevant FAK inhibitor, may be therapeutically beneficial by trig-
gering immune-mediated tumor regression.
RESULTS
FAK-Deficient SCC Tumors Undergo Regression in
an Immune-Competent Host
We used a syngeneic model of SCC in which the fak gene had
been deleted by Cre-lox recombination (McLean et al., 2004;
Serrels et al., 2012) and mutant tumor cell lines generated. We
monitored tumor growth following injection of 13 106 FAK-defi-
cient cells (FAK/) or FAK-deficient cells that re-expressed
wild-type FAK (FAK-WT) at comparable levels to endogenous
FAK in both CD-1 nude and FVB (syngeneic) host mouse strains.
In CD-1 nude mice, SCC FAK/ tumor growth was character-
ized by amodest growth delay (Figure 1A) as reported previously
(Serrels et al., 2012). By contrast, in FVB mice, SCC FAK/ tu-
mor growthwas characterized by an initial period of growth in the
first 7 days followed by complete regression by day 21 (Fig-
ure 1B). Thus, FAK expression is required for the survival andCell 163, 160–173, Segrowth of SCC tumors in FVB mice with
a functional adaptive immune system.
SCC FAK/ Tumor Regression Is
Dependent on CD8+ T Cells
To characterize the role of adaptive im-
munity in FAK/ SCC tumor regression,
we used antibody-mediated T cell deple-
tion in animals bearing FAK/ tumors
(Figures 1C and S1). Depletion of CD4+ T cells had no effect on
tumor growth. In contrast, depletion of CD8+ T cells, either alone
or in combination with CD4+ T cells, restored SCC FAK/ tumor
growth. This implies that cytotoxic CD8+ T cells were respon-
sible for regression of FAK/ tumors (Figure 1C) but does not
exclude an accessory role for CD4+ T cells. T cell depletion in
mice bearing SCC FAK-WT tumors (Figure 1D) revealed that:
(1) depletion of CD8+ T cells, either alone or in combination
with CD4+ T cells, caused a significant increase in tumor growth
when compared to isotype-treated controls at day 14, and
(2) depletion of CD4+ T cells alone caused regression of FAK-
WT SCC tumors by day 21. This implied that FAK-expressing
tumors were also under negative pressure from the immune sys-
tem and that cells from the CD4+ T cell compartment play a role
in protecting FAK-WT tumors from immune-mediated regression
(reason discussed later; Figure 3).
Next, we re-challenged mice with 1 3 106 SCC FAK-WT cells
after regression of primary FAK/ SCC tumors, following 7 days
of tumor-free survival after the tumors had regressed (Figure 1E,
top andmiddle graphs). Neither FAK-deficient nor FAK-express-
ing SCC cells were able to grow after the mice had been pre-
challenged with SCC FAK/ cells. As controls, SCC FAK-WT
and FAK/ cells were injected at day 28 into mice with no
pre-challenge, and these grew as expected (Figure 1E, bottom).ptember 24, 2015 ª2015 The Authors 161
This implies that, following FAK/ SCC tumor regression, host
mice remain immunized against further tumor challenge
because immunological memory had been established. It is
possible that either broad immunization against SCCs may
have occurred or, more likely, that the FAK/ and FAK-WT
SCCs shared common antigen(s) that are expressed irrespec-
tive of FAK status. We conclude that FAK enables SCC cancer
cells to suppress an adaptive immune response rather than to
circumvent it through evading recognition per se. SCC FAK/
cells in which a FAK kinase-deficient mutant was re-expressed
(SCC FAK-KD) initially grew and then regressed with kinetics
that were only modestly delayed when compared to FAK/
cells, indicating that immune suppression depends on FAK ki-
nase activity (Figure 1F).
We next investigated the nature of the T cell response within
tumors derived from all three SCC cell lines using FACS analysis
on disaggregated tumor tissue taken at day 7. We did not
observe a significant change in the percentage of total CD4+
T cells (Figures 2A and S2 and Table S2) or the percentage of
CD4+ T cells that expressed the activation marker CD69 (Fig-
ure 2B). In contrast, we did observe a significant increase in
the proportion of effector CD4+CD44hiCD62Llow T cells in SCC
FAK/ and FAK-KD tumors when compared to FAK-WT tumors
(Figures 2C and S2 and Table S2). Analysis of tumor-infiltrating
CD8+ T cells revealed a significant increase in SCC FAK/
and SCC FAK-KD tumors when compared to SCC FAK-WT tu-
mors (Figures 2D and S2 and Table S2), indicative of a height-
ened cytotoxic anti-tumor immune response. Staining with the
activation marker CD69 identified the presence of CD8+CD69+
T cells in all tumors (Figure 2E). Further analysis revealed an in-
crease in percentage of effector CD8+CD44hiCD62Llow T cells
in SCC FAK/ and SCC FAK-KD tumors when compared to
SCC FAK-WT tumors (Figures 2F and S2 and Table S2), espe-
cially when effector CD8+ T cell numbers were normalized to
account for the observed changes in total CD8+ T cells and pre-
sented as a ‘‘fold change’’ (Figure 2G). However, while SCC
FAK/ and SCC FAK-KD tumors had increased effector CD8+
T cells, there were activated CD8+ T cells present in all of the
SCC tumors, raising the question of why SCC FAK-WT tumors
do not succumb to the cytotoxic CD8+ T cell response.
It is now established that not only the quantity of tumor-infil-
trating CD8+ T cells is important, but also their ‘‘quality.’’
Tumor-induced T cell exhaustion has been reported in a number
of tumor types, including melanoma (Fourcade et al., 2010) and
ovarian cancer (Matsuzaki et al., 2010), and is characterized by
expression of co-inhibitory surface receptors, including pro-
grammed death receptor 1 (PD-1), lymphocyte-activation gene
3 (LAG-3), and T cell immunoglobulin mucin-3 (Tim-3), either
alone or in combination (Fourcade et al., 2010; Sakuishi et al.,
2010; Wherry, 2011). Analysis of these markers on antigen-
primed CD8+CD44hi T cells infiltrating SCC FAK-WT, FAK/,
and FAK-KD tumors revealed increased surface expression of
PD-1, LAG-3, and Tim-3 in CD8+CD44hi T cells present in SCC
FAK-WT tumors (Figures 2H–2J). Together, our data imply that
antigen-primed CD8+CD44hi T cells infiltrating SCC FAK-WT tu-
mors exhibit a heightened state of exhaustion indicative of a
dysfunctional T cell response. Linked to their exhausted state,
there was also evidence of decreased proliferation of CD8+162 Cell 163, 160–173, September 24, 2015 ª2015 The AuthorsT cells isolated from SCC FAK-WT tumors (judged by Ki-67
staining in Figure 2K).
Histological staining of tumor sections taken at day 7 revealed
that: (1) CD8+ T cells are present throughout all tumors, and
(2) while CD8+ T cells infiltrating SCC FAK-WT tumors appear
predominantly as individual cells, CD8+ T cells infiltrating SCC
FAK/ and FAK-KD tumors are clustered (Figure 2L). Thus,
the ability of SCC FAK-WT tumors to evade the anti-tumor im-
mune response is not due to limited CD8+ T cell penetration
into these tumors.
FAK Expression Drives Establishment
of an Immuno-Suppressive Environment
Macrophages, myeloid-derived suppressor cells (MDSC), and
Tregs with intrinsic immuno-suppressive capabilities can pro-
mote tumor development by inhibiting cytotoxic CD8+ T cell ac-
tivity in mouse and humans (Beyer and Schultze, 2006; Biragyn
and Longo, 2012; Marigo et al., 2008). Flow cytometric analysis
revealed no differences in macrophage or MDSC populations
that correlated with tumor regression (Figures 3A, 3B, S3, and
S4 and Table S2), although this does not rule out an accessory
role for these cells in eventual tumor clearance. However, we
did find a significantly greater number of CD4+FoxP3+CD25+
Tregs in SCC FAK-WT tumors (Figures 3C and S4 and Table
S2) when compared with FAK/ and FAK-KD tumors (Fig-
ure 3C). Tregs have been associated with the development of
CD8+ T cell exhaustion (Sakuishi et al., 2013) and may therefore
be linked to the CD8+ T cell exhaustion that we observed in SCC
FAK-WT tumors (Figures 2H–2J). We next calculated the ratio of
CD8+ T cells to Tregs (Figure 3D), as this has been reported to
correlate with poor prognosis in a number of tumor types (Sato
et al., 2005; Shah et al., 2011). We found a substantially lower
CD8+ T cell to Treg ratio in SCC FAK-WT tumors when compared
to SCC FAK/ and SCC FAK-KD tumors, which correlated with
outcome in terms of tumor tolerance versus immune-mediated
tumor regression.
Tregs Protect FAK-WT Tumors from Immune-Mediated
Regression
We next examined SCC FAK-WT tumor growth in animals
treated with an anti-CD25 antibody to deplete Tregs (Figure 3E).
Depletion of CD25+ cells led to regression of SCC FAK-WT
tumors. Therefore, FAK-dependent Tregs are required for the
growth of FAK-WT-expressing tumors by creating an im-
muno-suppressive environment that impairs cytotoxic CD8+
T cell activity. This role of CD4+ Tregs is the likely reason for ef-
fects of the CD4-depleting antibody in promoting regression of
SCC FAK-WT tumors (Figure 1D). We note that high Treg levels
have been reported in a number of solid tumor types (Beyer
and Schultze, 2006) and that elevated Tregs are linked to
poor clinical outcome (Beyer and Schultze, 2006; Sato et al.,
2005).
We demonstrated that Tregs derived from SCC FAK-WT tu-
mors expressed the transcription factor (TF) Helios (Figure S5A),
indicative of thymic origin (Thornton et al., 2010). Thus, we hy-
pothesized that FAK may drive the recruitment and expansion
of the intra-tumoral Tregs by influencing the availability of
secreted factors.
Figure 2. FAK-Depleted Tumors Exhibit a Heightened CD8+ T Cell Response
(A) FACS quantification of total intra-tumoral CD4+ T cells.
(B) FACS quantification of CD69+ cells as a percentage of CD4+ T cells.
(C) FACS quantification of CD4+CD44hiCD62Llow, CD4+CD44hiCD62Lhi, CD4+CD44lowCD62Llow T cell subpopulations.
(D) FACS quantification of total intra-tumoral CD8+ T cells.
(E) FACS quantification of CD69+ cells as a percentage of CD8+ T cells.
(F) Quantification of CD8+CD44hiCD62Llow, CD8+CD44hiCD62Lhi, CD8+CD44lowCD62Llow T cell subpopulations.
(G) Changes in effector (CD8+CD44hiCD62Llow) CD8+ T cells normalized to total CD8+ T cell proportions.
(H) FACS quantification of PD-1+LAG-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 6 tumors.
(I) FACS quantification of PD-1+Tim-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 3 tumors.
(J) FACS quantification of PD-1+Tim-3+LAG-3+ T cells as a percentage of CD8+CD44hi tumor-infiltrating T cells. n = 3 tumors.
(K) FACS quantification of Ki-67+ cells as a percentage of tumor-infiltrating CD8+ T cells. n = 3 tumors.
(L) Representative histological staining of CD8 in frozen sections from SCC FAK-WT, SCC FAK/, and SCC FAK-KD tumors. Dashed white lines demark tumor
boundary.
Scale bars, 500 mm. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (C and F, CD44hiCD62Llow only). Data
are represented as mean ± SEM; n = 5 tumors unless stated.FAK Regulates the Transcription of Chemokines and
Cytokines to Control Tregs
To address how FAK activity in SCC cancer cells promotes
elevated intra-tumoral Tregs, we next analyzed global transcrip-tional profiles of SCC FAK-WT and SCC FAK/ cells using Affy-
metrix GeneChip microarrays (Figure 4A). FAK expression re-
sulted in the upregulation of 498 genes and the downregulation
of 598 genes (p < 0.01). The upregulated transcript set in SCCCell 163, 160–173, September 24, 2015 ª2015 The Authors 163
Figure 3. FAK Regulates the Immuno-Sup-
pressive Microenvironment
(A) FACS quantification of Ly6Chi and Ly6Clow
macrophage populations expressed as a per-
centage of tumor-infiltrating CD45+ leukocytes.
(B) FACS quantification of Ly6ChiGr1low (M-MDSC)
and Ly6CintGr1hi (G-MDSC) populations ex-
pressed as a percentage of tumor-infiltrating
CD45+ leukocytes.
(C) Quantification of CD4+CD25+FoxP3+ Tregs
expressed as a percentage of tumor-infiltrating
CD4+ T cells.
(D) CD8+ T cell-to-Treg ratio calculated using
mean values from Figures 2D and 3C.
(E) SCC FAK-WT tumor growth in FVB mice
treated with anti-CD25 depleting antibody.
n = 6 tumors. * or +p < 0.05, ++p < 0.01, ***p <
0.001, **** or ++++p < 0.0001; Tukey-corrected
one-way ANOVA (A, *, Ly6Chi; +, Ly6Clow). Data are
represented as mean ± SEM; n = 5 tumors unless
stated.FAK-WT cells was associated with a number of processes,
including cell migration, receptor binding, secretion, wounding,
and ovulation (Figure 4B, top). Analysis of this gene set revealed
the chemokine ligand group of genes to be significantly overrep-
resented (Figure 4B, bottom), which is interesting given that a
number of these chemokines and cytokines mediate both Treg
recruitment to tumors and induction of peripheral Tregs within
tumors (Goldstein et al., 2013; Ondondo et al., 2013).
To establish which chemokines and cytokines were regulated
by FAK and to address whether the FAK-dependent transcrip-
tional profile was linked to chemokine receptor expression on tu-
mor-infiltrating Tregs, we performed quantitative (q)RT-PCR
array analysis. Comparison of chemokine/cytokine transcript
levels between SCC FAK-WT and SCC FAK/ cells revealed a
subset of ligands increased >2-fold in SCC FAK-WT cells (Fig-
ure 4C). Several of these (Ccl1, Ccl5, Ccl7, Cxcl10) have roles
in Treg recruitment (Ondondo et al., 2013) (green arrowheads,
Figure 4C), while one (Tgfb2) has a reported role in peripheral in-
duction and expansion of Tregs (Goldstein et al., 2013) (red
arrowhead, Figure 4C). To complement this, comparison of
Tregs isolated from the thymus of normal FVB mice with those
isolated directly from SCC FAK-WT tumors revealed a chemo-
kine receptor switch (Figure 4D). We found increased expression
of the cognate receptors for five of the six chemokine ligands up-
regulated in SCC FAK-WT cells (Figure 4C). These receptor
changes may represent a switch from lymphoid homing recep-
tors, including Ccr7 and Cxcr4, toward expression of memory/
effector-type chemokine receptors, including Ccr2, Ccr5, Ccr8,
and Cxcr6, involved in recruitment to non-lymphoid tissues
and sites of inflammation. Network analysis of the relationship
between FAK-dependent chemokine ligand expression in SCC
cells and tumor-infiltrating Treg chemokine receptor expression
revealed the existence of a FAK-dependent paracrine signaling
axis between cancer cells and intra-tumoral Tregs based on che-164 Cell 163, 160–173, September 24, 2015 ª2015 The Authorsmokine ligand-receptor interactions (Figure 4E). Furthermore, (q)
RT-PCR analysis of Ccl5, Cxcl10, and Tgfb2 demonstrated that
their expression was dependent on FAK kinase activity (Fig-
ure 4F). We note that disruption of the Ccl5/Ccr5 axis in a model
of pancreatic adenocarcinoma results in reduced intra-tumoral
Tregs and slows tumor growth (Tan et al., 2009), implying that
FAK-dependent regulation of this paracrine signaling axis may
be more generally important. Thus, FAK activity regulates the
expression of a subset of chemokines that can specifically
mediate crosstalk between tumor cells and tumor-infiltrating
Tregs. This likely has importance in recruitment and retention
of CD4+FoxP3+CD25+ Tregs into SCC FAK-WT tumors.
Nuclear FAK Regulates the Transcription of Ccl5
and TGFb2 to Increase Tregs
The finding that the Tregs enriched in SCC FAK-WT tumors
were likely recruited into SCC FAK-WT tumors led us to
consider a potential role for Ccl5 that has been implicated in
the recruitment and expansion of CD4+FoxP3+CD25+ Tregs
(Tan et al., 2009), via the paracrine signaling axis that we iden-
tified. We found that efficient knockdown of Ccl5 using two
independent shRNA hairpins (P1 and P2, Figure 5A) resulted
in SCC FAK-WT shRNA-Ccl5 tumor regression by days 21–27
(Figure 5B). We measured the absolute number of Tregs in
SCC FAK-WT shRNA-Ccl5 tumors at day 7 and found that there
was a substantial reduction in both Ccl5-depleted tumors when
compared with empty vector control SCC FAK-WT pLKO tu-
mors (Figure 5C).
Expanding on these findings, shRNA-mediated knockdown of
Tgfb2 expression in SCC FAK-WT cells also influenced tumor
growth (Figures S5B and S5C). Partial knockdown of TGFb2
had complex effects, which resulted in one of two outcomes.
One group (Figure S5C, dashed blue line), grew more rapidly
and ulcerated, leading to removal from study at day 14. In the
Figure 4. FAK Regulates Transcription of Cytokines Implicated in Treg Recruitment and Expansion
(A) Transcriptomic profiling of SCC FAK-WT and SCC FAK/ cells.
(B) Functional enrichment analysis of genes upregulated in SCC FAK-WT cells (bottom gray bar in A). Overrepresented biological processes are displayed as a
heatmap (log10-transformed color scale) (top); asterisks indicate presence of cytokine-related genes. Overrepresented gene families are displayed as a bar chart
(bottom). p < 0.05; Benjamini–Hochberg-corrected hypergeometric tests.
(C) qRT-PCR array analysis of cytokine and chemokine expression in SCCFAK-WT andSCC FAK/ cells. Gray bar indicates cluster of genes upregulated in SCC
FAK-WT cells; cytokine and chemokine gene names are listed. Green arrowheads indicate reported roles in Treg recruitment; red arrowhead indicates reported
role in peripheral Treg induction.
(D) qRT-PCR array analysis of chemokine and receptor expression in tumor- and thymus-derived Tregs. Gray bar indicates cluster of genes upregulated in tumor-
derived Tregs; receptor gene names are listed.
(E) Interaction network analysis of chemokine ligand gene expression detected in SCC cells (circles, left) and corresponding receptor gene expression detected in
Tregs (squares, right). Genes are ordered vertically by fold change. Light gray lines connect receptor-ligand pairs; green lines indicate pairs upregulated at least
2-fold in SCC FAK-WT cells and tumor-derived Tregs.
(F) qRT-PCR analysis of selected cytokine and chemokine gene expression in SCC cells. ***p < 0.001, ****p < 0.0001; Tukey-corrected one-way ANOVA. Data are
represented as mean ± SEM.
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Figure 5. Nuclear FAK Regulates Transcription of Ccl5, which Is Required for Treg Recruitment and Tumor Growth
(A) qRT-PCR analysis of Ccl5 gene expression knockdown in SCC FAK-WT cells stably expressing two independent shRNA constructs targeting Ccl5 (P1
and P2).
(B) SCC FAK-WT shRNA-Ccl5 tumor growth in FVB mice. n = 6 tumors.
(C) FACS quantitation of tumor-infiltrating Treg numbers from SCC FAK-WT shRNA-Ccl5 tumors. Data represent a single value from six pooled tumors.
(D) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC FAK/, and SCC FAK-NLS cells.
(E) qRT-PCR analysis of Ccl5 gene expression in SCC FAK-NLS cells.
(F) Tumor growth of SCC FAK-NLS cells in FVB mice.
(G) Western blotting of cytoplasmic, nuclear, and total protein fractions from SCC FAK-WT, SCC FAK/, and SCC FAK-KD cells.
(H) Western blotting of whole-cell (WC) and nuclear (Nuc) protein fractions from SCC FAK-WT cells and primary skin keratinocytes. 60 s exposure time is shown
for all samples; additional 10 min exposure time is shown for FAK in keratinocyte samples. GAPDH, cytoplasmic; PARP, nuclear.
***p < 0.001, ****p < 0.0001; Tukey-corrected one-way ANOVA. Data are represented as mean ± SEM unless stated.other group that did not display such frank ulceration, we
observed tumor regression by day 27 (Figure S5C, dashed red
line). Analysis of Treg levels in SCC FAK-WT shRNA-TGFb2 tu-
mors at day 7 (regardless of initial growth characteristics) re-
vealed that TGFb2 knockdown was also associated with a
reduction in CD4+FoxP3+CD25+ Tregs (Figure S5D). Therefore,166 Cell 163, 160–173, September 24, 2015 ª2015 The Authorswhile the effects of reducing TGFb2 expression aremore compli-
cated than for Ccl5, FAK-dependent TGFb2 expression does
contribute to elevated CD4+FoxP3+CD25+ Tregs in SCC FAK-
WT tumors; and in the subset of mice bearing tumors that
were able to complete the study, TGFb2 knockdown also caused
tumor regression.
Our findings that FAK regulated the transcription of cytokines
and chemokines (including Ccl5 and TGFb2) that were associ-
ated with elevated intra-tumoral Tregs and tumor tolerance led
us to consider a possible role for nuclear FAK in regulating the
transcription of these genes. Based on previous reports (Lim
et al., 2008), which identified putative NLSs within the FERM
domain of FAK, we constructed an optimally nuclear targeting-
impaired mutant FAK by replacing two arginines (positions 177
and 178) and four lysines (positions 190, 191, 216, and 218)
with alanines (termed FAK-NLS). Western blotting of cyto-
plasmic and nuclear fractions confirmed that the FAK-NLS
mutant was indeed defective in nuclear localization (Figure 5D).
Subsequent (q)RT-PCR analysis of Ccl5 and Tgfb2 expression
in SCC cells expressing only FAK-NLS revealed that FAK nuclear
localization was required for transcription of these genes (Fig-
ures 5E and S5E, respectively). Thus, nuclear FAK drives the
transcription of Ccl5 and TGFb2, which are required for recruit-
ment and expansion of immuno-suppressive Tregs into SCC tu-
mors, altering the balance between CD8+ T cells and Tregs in
favor of tumor tolerance. In support of this, growth of SCC
FAK-NLS tumor cells was similar to that of SCC FAK/, with ul-
timate tumor regression (Figure 5F). This confirmed that it was
nuclear FAK that afforded protection from the anti-tumor im-
mune response. Western blotting of cytoplasmic and nuclear
fractions from SCC FAK-KD showed that the kinase-deficient
mutant was able to localize to the nucleus, so we conclude
that the immune modulatory effects of FAK are dependent on
FAK kinase activity in the nucleus (Figure 5G).
We next examined nuclear FAK levels in primary skin keratino-
cytes, the normal cellular counterparts of the SCC cells used
here, and did not find detectable nuclear FAK (Figure 5H).
Thus, abundant nuclear localization, and therefore the capacity
to exert regulatory control over chemokine and cytokine expres-
sion, is likely a feature of oncogenic transformation in skin kera-
tinocytes. This suggests that the nuclear functions of FAK that
we have identified—namely, regulating transcription of chemo-
kine/cytokine networks—may be associated with the cancerous
state when FAK is highly expressed.
Nuclear FAK Interacts with a Network of Ccl5
Transcriptional Regulators
Having established an important role for the nuclear FAK-
dependent transcription of Ccl5 in mediating recruitment and
expansion of intra-tumoral Tregs, we wanted to determine
how nuclear FAK could exert control over Ccl5 transcription.
Using sucrose gradients, we fractionated the nuclei of SCC
FAK-WT cells and demonstrated that nuclear FAK was present
in the chromatin-containing fraction (Figure 6A). Transcriptional
regulation of Ccl5 is mediated predominantly through six short
regulatory elements contained within a region of the Ccl5 pro-
moter spanning 300 base pairs (Fessele et al., 2002). These
regulatory elements contain binding sites for a number of
TFs, including AP-1, C/EBP, IRF-1, NF-kB, and TATA box-bind-
ing protein (TBP), which is part of the transcription factor IID
complex (TFIID). Using FAK immunoprecipitation and quantita-
tive label-free mass spectrometry, we identified FAK binding
partners in purified nuclear extracts and contextualized these
by mapping onto a network of proteins associated with pre-dicted Ccl5 TFs (constructed in silico; Figure 6B). This integra-
tive approach identified a subset of Ccl5 TFs and regulators of
these that interact with FAK in SCC cell nuclei (Figures 6C, S6
and Table S1). Interaction network analysis of this protein sub-
set revealed nuclear FAK binding partners with roles in multiple
transcriptional pathways, including regulators of AP-1, C/EBP,
IRF-1/-7, NF-kB/Rel, and TFIID. Thus, we identified nuclear
FAK binding partners that can interact, directly or indirectly,
with five of the six main regulatory elements reported to control
transcription of Ccl5 in multiple cell types (Fessele et al., 2002).
Given that our interaction network was somewhat dominated
by proteins associated with the TFIID pathway, including three
TBP-associated factors (TAFs) (Figures 6C and S6), we used
co-immunoprecipitation to confirm the interaction of nuclear
FAK with one of these, TAF9, a core component of the TFIID
complex (D’Alessio et al., 2009) (Figure 6D). Our data show
that FAK binds to core components of the transcriptional ma-
chinery, many of which are known to be located on the pro-
moter of genes undergoing active transcription and that are
known or predicted to regulate Ccl5. Therefore, in SCC cells,
nuclear FAK associates with chromatin and is physically linked
to a network of TFs and their regulators known to modulate
Ccl5 expression.
Small-Molecule FAK Kinase Inhibitor Promotes
Immune-Mediated Tumor Clearance
Therapeutic targeting of FAK kinase activity using small-mole-
cule inhibitors will inhibit FAK signaling not only in tumor cells,
but also potentially in multiple host cell types. To complement
expression of the FAK-KD mutant protein in the cancer cells
and investigate whether a FAK inhibitor could induce immune-
mediated regression of SCC tumors, we used the FAK/Pyk2 ki-
nase inhibitor VS-4718 (Shapiro et al., 2014), which is currently
in clinical development. Mice were treated with VS-4718 at
75 mg/kg for 24 hr prior to injection of 1 3 106 FAK-WT or
FAK/ SCC tumor cells and twice daily thereafter. This resulted
in VS-4718-induced regression of SCC FAK-WT tumors by day
24 (Figure 7A). Following cessation of VS-4718 treatment, no
tumor regrowth was observed (data not shown). SCC FAK/ tu-
mor growth and clearance was not greatly affected by VS-4718
treatment, suggesting that the anti-tumor effects of VS-4718 can
be explained by FAK inhibition in tumor cells. Activity of VS-4718
was confirmed using an ELISA to measure FAK autophosphory-
lation on tyrosine-397 in tumor lysates from mice treated with
75 mg/kg VS-4718 (Figure S7). Regression of VS-4718-treated
SCC tumors was not accompanied by loss of cell viability at
day 7, as measured by FACS using a viability stain following tu-
mor disaggregation (Figure 7B). There was a significant but small
increase in leukocytes in VS-4718-treated SCC FAK-WT tumors
(Figure 7C) and a significant increase in total CD4+ T cells (Fig-
ures 7D andS2 and Table S2) and effector CD4+CD44hiCD62Llow
T cells (Figures 7E and S2 and Table S2). A significant increase in
CD8+ T cells was also evident in SCC FAK-WT VS-4718-treated
tumors (Figures 7F and S2 and Table S2), although there was no
change in effector CD8+CD44hiCD62Llow T cells (Figures 7G and
S2 and Table S2). Crucially, there was a significant reduction in
CD4+CD25+FoxP3+ Treg cells in VS-4718-treated SCC FAK-
WT tumors, which was similar to that observed in vehicle andCell 163, 160–173, September 24, 2015 ª2015 The Authors 167
Figure 6. Nuclear FAK Interacts with Regulators of Ccl5 Transcription
(A) Sucrose fractionation of soluble chromatin prepared from SCC FAK-WT cell nuclei. Protein preparations recovered from each fraction were analyzed by
western blotting (top). DNA recovered from each fraction was analyzed by agarose gel electrophoresis (bottom, 1 kilobase [kb] and 100 base pair [bp] ladders
shown). Fraction 7 (black arrowhead) represents the chromatin-containing fraction.
(B) Schematic detailing the workflow used for proteomic analysis of the nuclear FAK interactome in the context of Ccl5 transcription factors (TFs).
(C) Interaction network analysis of proteins that bind FAK in the nucleus of SCC cells. PredictedCcl5 TFs (squares, bottom) and respective TF binders (circles, top)
enriched by at least 4-fold in nuclear FAK immunoprecipitations (SCC FAK-WT over SCC FAK/ controls; p < 0.05) are shown (stringent network). Ccl5 TFs not
detected (ND) are shown as gray squares. TF complexes or groups are indicated; proteins are labeledwith gene names for clarity. TF binders are aligned above TF
groups with which there are the greatest number of reported interactions. For full network, see Figure S6; for protein interaction list, see Table S1.
(D) Isolation of the TFIID component TAF9 by FAK immunoprecipitation (IP) from SCC FAK-WT cell nuclear extracts.VS-4718-treated SCC FAK/ tumors (Figures 7H and S4 and
Table S2).
Thus, VS-4718 promoted robust anti-tumor activity, with
similar immune cell changes to that observed upon FAK deletion
or expression of a kinase-deficient form of FAK. Furthermore,
anti-tumor efficacy of VS-4718 was also dependent on CD8+
T cells, and SCC FAK-WT tumors treated with VS-4718 on a
CD8+ T cell-depleted background exhibited a growth delay but168 Cell 163, 160–173, September 24, 2015 ª2015 The Authorsdid not undergo tumor regression (Figure 7I). We conclude that
the FAK kinase inhibitor targets mechanisms of immune
suppression andmay therefore represent a form of effective ‘‘im-
muno-modulatory’’ therapy that reduces Tregs in the tumor envi-
ronment. Importantly, the FAK kinase inhibitor does not affect
the cytotoxic function of antigen-primed CD8+ T cells. We also
found that VS-4718 treatment that was initiated 5 days post-
inoculation of 1 3 106 SCC FAK-WT cells, when these had
Figure 7. The FAK Kinase Inhibitor VS-4718 Leads to Immune-Mediated SCC Clearance
(A) SCC FAK-WT and SCC FAK/ tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 24 hr pre-tumor cell inoculation and
continued for the duration of the experiment.
(B) FACS analysis of cell viability from disaggregated tumors treated with either vehicle or VS-4718.
(C) FACS analysis of vehicle- or VS-4718-treated tumor-infiltrating leukocytes expressed as a percentage of viable CD45+ cells relative to the total number of
single cells.
(D) FACS analysis of tumor-infiltrating CD4+ T cells from vehicle- or VS-4718-treated tumors.
(E) FACS sub-categorization of tumor-infiltrating CD4+ T cells into CD45+CD3+CD4+CD8CD44hiCD62Llow, CD45+CD3+CD4+CD8CD44hiCD62Lhi, and
CD45+CD3+CD4+CD8CD44lowCD62Llow populations.
(F) FACS analysis of tumor-infiltrating CD8+ T cells from vehicle- or VS-4718-treated tumors.
(G) FACS sub-categorization of tumor-infiltrating CD8+ T cells into CD45+CD3+CD4CD8+CD44hiCD62Llow, CD45+CD3+CD4CD8+CD44hiCD62Lhi, and
CD45+CD3+CD4CD8+CD44lowCD62Llow populations.
(H) FACS analysis of tumor-infiltrating CD4+CD25+FoxP3+ Tregs expressed as a percentage of tumor-infiltrating CD4+ T cells.
(I) SCC FAK-WT tumor growth in FVB mice treated with either vehicle or VS-4718 and either isotype control or CD8-depleting antibodies.
(J) SCC FAK-WT and SCC FAK/ tumor growth in FVB mice treated with either vehicle or VS-4718. Treatment started 5 days post-tumor cell inoculation (gray
dashed line) and continued for the duration of the experiment.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant; Tukey-corrected one-way ANOVA (E and G, CD44hiCD62Llow only). Data are represented as
mean ± SEM; n = 6 tumors.
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already formed palpable tumors of50mm3, led to complete tu-
mor regression (Figure 7J).
DISCUSSION
We show that nuclear FAK in SCC cancer cells drives the tran-
scription of chemokines and cytokines, including Ccl5 and
TGFb2, which promote the formation of an immuno-suppressive,
pro-tumorigenic microenvironment. This is dependent on FAK
kinase activity, and expression of a catalytically inactive mutant
FAK protein (FAK-KD) or treatment with a small-molecule inhib-
itor causes tumor regression. This is effective even when tumors
are already established, raising the exciting possibility that tar-
geting of FAK kinase activity may have immune-mediated anti-
tumor efficacy in patients. We established that nuclear FAK is
associated with chromatin and interacts with a number of TFs
and transcriptional regulators, including components of the
TFIID complex, that are linked to regulation of Ccl5 expression.
Our data imply that FAK interacts with core transcriptional
machinery to influence gene transcription and promote tumor
immune escape.
Historically, FAK has been recognized as an adhesion-related
non-receptor protein tyrosine kinase that clusters at focal adhe-
sion (FA) structures and regulates cancer-associated processes,
including adhesion, migration, invasion, survival, and prolifera-
tion (reviewed in Frame et al., 2010). FAK was also found to
translocate to the nucleus (Lim et al., 2008; Luo et al., 2009b),
leading to the idea of nuclear functions for FAK within the nu-
cleus. Our data show that, at least in cancer cells, FAK regulates
inflammatory transcriptional programs associated with genera-
tion and maintenance of a pro-tumorigenic and immuno-sup-
pressive microenvironment. FAK associates with chromatin,
and in the context of Ccl5 expression, it interacts with a number
of TFs, and regulators of TFs, that bind regulatory elements in the
Ccl5 promoter (Fessele et al., 2002). Our data imply that FAK ex-
ists in complexes with a number of TAF proteins, including TAF9
and TAF12, key components of the core promoter complex
TFIID that serves to initiate transcription by driving recruitment
of chromatin remodeling complexes, coactivators, and RNA po-
lymerase II to the promoter (D’Alessio et al., 2009). Therefore,
FAK interacts with components of the core transcriptional
machinery in order to drive transcription of chemokines and cy-
tokines that contribute to recruitment of Tregs into the tumor
environment, promoting immunological tolerance and permitting
tumor growth.
Recently, nuclear accumulation of active FAK (phosphory-
lated on Tyr-397) within tumor cells of patients with colorectal
cancer was reported to correlate with poor prognosis (Albasri
et al., 2014), highlighting the need to understand the nature of
FAK’s role within the nucleus. Studies using endothelial cells,
muscle cells, and fibroblasts have previously reported low
steady-state levels of nuclear FAK that are substantially
increased in response to cellular stress (Lim, 2013; Lim et al.,
2008; Luo et al., 2009b). Our work implies that oncogenic stress
is another route to inducing high levels of nuclear FAK and that
this, in turn, can influence transcriptional programs, such as the
chemokine and cytokine networks that control the tumor
microenvironment.170 Cell 163, 160–173, September 24, 2015 ª2015 The AuthorsA number of therapeutic strategies targeting components of
the immuno-suppressive tumor microenvironment are currently
being tested, with the aim of restoring anti-tumor immunity by
releasing the break on CD8+ T cell cytotoxic activity. In pre-clin-
ical models of cancer, targeting Tregs (Ali et al., 2014; Bos et al.,
2013) has shown anti-tumor efficacy, either alone or when used
in combination with agents that enhance CD8+ T cell activation.
A clinical study combining agents targeting cytotoxic-T-lympho-
cyte-associated antigen 4 (CTLA-4), which is thought to influ-
ence Treg function (Peggs et al., 2009; Quezada et al., 2006;
Simpson et al., 2013; Wing et al., 2008), and PD-1, which blocks
signals that inhibit T cell function, has reported impressive re-
sponses in patients with advanced melanoma (Wolchok et al.,
2013). However, this combination of checkpoint blockade anti-
bodies elicits substantial side effects in >50% of patients, high-
lighting the need to find alternative combinations with improved
tolerability. We have shown that targeting FAK kinase activity has
the potential to modulate intra-tumoral Treg levels, resulting in
robust CD8+ T cell anti-tumor immunity, while others have re-
ported previously that FAK kinase inhibitors block monocyte/
macrophage and cancer-associated fibroblast recruitment into
tumors by virtue of FAK’s role in regulating their migration
(Stokes et al., 2011). Taken together, these findings suggest
that targeting the pleiotropic cellular functions of FAK may
have a broad impact on the immuno-suppressive tumor micro-
environment, differentiating these agents frommany therapeutic
approaches that target single immune cell populations.
Targeting a molecular pathway that is upregulated in cancer
cells may provide tumor specificity and help to overcome
some of the potential issues with severe autoimmunity when
modulating immune cell populations. FAK inhibitors, such as
VS-4718, are in clinical development. VS-4718 is currently in a
phase I dose escalation clinical trial in patients with solid tumors
(www.clinicaltrials.gov NCT01849744). Our findings provide
good rationale for pre-clinical and clinical testing of FAK kinase
inhibitors alongside agents that stimulate CD8+ T cell activity,
such as the checkpoint blockade therapies that target PD-1
and CTLA-4, which are both in clinical development (Pardoll,
2012).
EXPERIMENTAL PROCEDURES
Experiments involving animals were carried out in accordance with the
UKCCCR guidelines by approved protocol (HO PL 60/4248). Brief experi-
mental procedures are listed here. For details, please see the Supplemental
Experimental Procedures.
Generation of FAK Nuclear Localization Mutant
Mutations were introduced into FAK-WT at R177A, R178A, K190A, K191A,
K216A, and K218A using PCR-based site-directed mutagenesis.
Cell Lines
Isolation and generation of the FAKSCC cell model is described in Serrels et al.
(2012). Keratinocyte cultureswere prepared as detailed inMcLean et al. (2004).
Western Blot Analysis
To prepare whole-cell lysates, cells were washed in cold PBS and lysed in
RIPA buffer. Cytoplasmic and nuclear extracts were prepared as described
in Lim et al. (2008). Lysates were resolved by gel electrophoresis, transferred
to nitrocellulose, and probed with respective antibodies.
Subcutaneous Tumor Growth
Cells were injected into both flanks of either CD-1 nude mice or FVB mice and
tumor growth measured twice-weekly. Animals were sacrificed when tumors
reached maximum allowed size or when signs of ulceration were evident.
For treatment with VS-4718, drug was prepared in 0.5% carboxymethyl cellu-
lose + 0.1% Tween 80 and mice treated at 75 mg/kg BID by gavage. No signs
of toxicity were observed.
Tumor Growth following Re-Challenge
SCC FAK/ cells were injected into the left flank of FVBmice. Following tumor
regression, mice were left for 7 days before being challenged with SCC FAK-
WT or FAK/ cells injected into the right flank. Tumor growth was measured
twice-weekly. Control groups were injected into both flanks at day 28 using
mice that had not been pre-challenged with SCC FAK/ cells.
CD4+, CD8+, and CD25+ T Cell Depletion
T cell depletion was achieved following IP injection of 150 mg of depleting anti-
body into female age-matched FVB mice for 3 consecutive days and was
maintained by further IP injection at 3 day intervals until the study was termi-
nated. SCC FAK-WT or FAK/ cells were injected into both flanks 6 days after
initial antibody treatment and tumor growth measured. The extent of T cell
depletion was determined at the end of the study using FACS (Figure S1).
FACS Analysis of Immune Cell Populations
Tumors established following injection of SCC cells into both flanks of an FVB
mouse were removed at day 7. Tumor tissue was processed to obtain single
cell suspension for staining and subsequent FACS analysis (antibodies listed
in Table S2).
Gene Expression Profiling
RNA was analyzed using the GeneChip Mouse Genome 430 2.0 Array.
Normalized data for differentially expressed genes were median centered
and clustered using Cluster 3.0 and Java TreeView. Functional enrichment
analysis was performed using ToppGene.
Quantitative RT2-PCR Array Analysis of Cytokine, Chemokine,
and Chemokine Receptor Expression
RNA prepared from SCC cells was analyzed using the mouse cytokine and
chemokine RT2 Profiler PCR Array and that from isolated Tregs was analyzed
using the mouse chemokine and receptor array. Relative gene expression
(2DCt) values were log transformed, median centered, and subjected to hier-
archical clustering as for microarray analysis. An interactome of chemokine
ligands and receptors was constructed using the IUPHAR/BPS Guide to Phar-
macology database and curated from the literature, onto which expression
data for detected genes were mapped and visualized using Cytoscape.
Expression of selected cytokine and chemokine genes was assessed by stan-
dard quantitative RT-PCR.
shRNA-Mediated TGFb2 and Ccl5 Knockdown
Cells were subject to two rounds of lentiviral infection prior to selection with
puromycin. shRNA constructs used were part of the pLKO lentiviral TRC
library.
Preparation and Fractionation of Nuclei and Chromatin
Nuclei were prepared as described (Gilbert et al., 2003) but with a reduced
concentration (0.05%) of NP-40 in nuclei buffer B. Soluble chromatin was pre-
pared as described (Gilbert et al., 2004) and fractionated on a sucrose step
gradient to separate soluble and chromatin-associated nuclear proteins.
DNA was recovered from fractions and subjected to agarose gel electropho-
resis. Protein was purified using TCA precipitation. Samples were analyzed
by SDS-PAGE and blotted using anti FAK, HP1a, and histone H3 antibodies.
Proteomic Analysis of Nuclear FAK Protein Complexes
FAK nuclear protein complexes were subjected to on-bead proteolytic diges-
tion, desalting, and liquid chromatography-tandem mass spectrometry, as
described (Turriziani et al., 2014). For interaction network analysis, Ccl5 tran-
scription factors were extracted from the DECODE database and used to seeda network of 1,000 transcription factor-related proteins using the GeneMANIA
plugin in Cytoscape. Proteins specifically isolated in nuclear FAK protein com-
plexes were mapped onto the interactome, and those with physical or pre-
dicted direct or indirect interactions with Ccl5 transcription factors were
analyzed using the NetworkAnalyzer plugin in Cytoscape.
CD8 T Cell Fluorescent Immunohistochemistry
Tumors were removed 7 days post-implantation and frozen by submersing in
liquid nitrogen. Tumor sections were cut, processed and stained. They were
imaged using an Olympus FV1000 confocal microscope.
ACCESSION NUMBERS
The microarray data discussed in this manuscript has been deposited in
NCBI’s Gene Expression Omnibus and is accessible through GEO series
accession number GEO: GSE71662.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cell.2015.09.001.
AUTHOR CONTRIBUTIONS
A.S. andM.C.F. devised and oversaw the project. A.S., T.L., B.S., A.B., S.M.A.,
R.J.B.N., and M.C.F. designed the experiments with contributions from E.M.,
J.A.P., V.G.B., and N.G. A.S., T.L., B.S., A.B., R.C.M., and A.v.K. performed
experiments with contributions from L.G.-C., M.C., M.M., and J.E.R. A.S.,
T.L., B.S., A.B., R.C.M., A.v.K., and A.H.S. analyzed the data. A.B. and
A.H.S. performed bioinformatic analysis. A.S. and M.C.F. wrote the manu-
script with contributions from T.L., B.S., and A.B.; all authors commented on
and approved the final version. We consider that A.S. and T.L. made equal
contributions and that B.S. and A.B. made equal contributions.
ACKNOWLEDGMENTS
This work was supported by Cancer Research UK (Grant no. C157/A15703 to
M.C.F.), European Research Council (Grant no. 29440 Cancer Innovation to
M.C.F.) and Medical Research Council (Grant no. G1100084 to S.M.A.). We
thank Frederic Li Mow Chee for help with transcriptomic analysis, Amaya Gar-
cı´a-Mun˜oz for help with mass spectrometry, Elisabeth Freyer for help with
FACS, and Arkadiusz Welman for help with manuscript preparation. J.E.R.
and J.A.P. are employees of Verastem Inc.
Received: March 6, 2015
Revised: July 17, 2015
Accepted: August 27, 2015
Published: September 24, 2015
REFERENCES
Albasri, A., Fadhil, W., Scholefield, J.H., Durrant, L.G., and Ilyas, M. (2014). Nu-
clear expression of phosphorylated focal adhesion kinase is associated with
poor prognosis in human colorectal cancer. Anticancer Res. 34, 3969–3974.
Ali, K., Soond, D.R., Pin˜eiro, R., Hagemann, T., Pearce, W., Lim, E.L., Bouabe,
H., Scudamore, C.L., Hancox, T., Maecker, H., et al. (2014). Inactivation of PI(3)
K p110d breaks regulatory T-cell-mediated immune tolerance to cancer.
Nature 510, 407–411.
Ashton, G.H., Morton, J.P., Myant, K., Phesse, T.J., Ridgway, R.A., Marsh, V.,
Wilkins, J.A., Athineos, D., Muncan, V., Kemp, R., et al. (2010). Focal adhesion
kinase is required for intestinal regeneration and tumorigenesis downstream of
Wnt/c-Myc signaling. Dev. Cell 19, 259–269.
Beyer, M., and Schultze, J.L. (2006). Regulatory T cells in cancer. Blood 108,
804–811.Cell 163, 160–173, September 24, 2015 ª2015 The Authors 171
Biragyn, A., and Longo, D.L. (2012). Neoplastic ‘‘Black Ops’’: cancer’s subver-
sive tactics in overcoming host defenses. Semin. Cancer Biol. 22, 50–59.
Bos, P.D., Plitas, G., Rudra, D., Lee, S.Y., and Rudensky, A.Y. (2013). Transient
regulatory T cell ablation deters oncogene-driven breast cancer and enhances
radiotherapy. J. Exp. Med. 210, 2435–2466.
Curiel, T.J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-
Hogan, M., Conejo-Garcia, J.R., Zhang, L., Burow, M., et al. (2004). Specific
recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege
and predicts reduced survival. Nat. Med. 10, 942–949.
D’Alessio, J.A., Wright, K.J., and Tjian, R. (2009). Shifting players and para-
digms in cell-specific transcription. Mol. Cell 36, 924–931.
Darrasse-Je`ze, G., and Podsypanina, K. (2013). How numbers, nature, and im-
mune status of foxp3(+) regulatory T-cells shape the early immunological
events in tumor development. Front. Immunol. 4, 292.
Fessele, S., Maier, H., Zischek, C., Nelson, P.J., and Werner, T. (2002). Regu-
latory context is a crucial part of gene function. Trends Genet. 18, 60–63.
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I.F., Sander,
C., Kirkwood, J.M., Kuchroo, V., and Zarour, H.M. (2010). Upregulation of
Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+
T cell dysfunction in melanoma patients. J. Exp. Med. 207, 2175–2186.
Frame, M.C., Patel, H., Serrels, B., Lietha, D., and Eck, M.J. (2010). The FERM
domain: organizing the structure and function of FAK. Nat. Rev. Mol. Cell Biol.
11, 802–814.
Gilbert, N., Boyle, S., Sutherland, H., de Las Heras, J., Allan, J., Jenuwein, T.,
and Bickmore, W.A. (2003). Formation of facultative heterochromatin in the
absence of HP1. EMBO J. 22, 5540–5550.
Gilbert, N., Boyle, S., Fiegler, H., Woodfine, K., Carter, N.P., and Bickmore,
W.A. (2004). Chromatin architecture of the human genome: gene-rich domains
are enriched in open chromatin fibers. Cell 118, 555–566.
Goldstein, J.D., Pe´rol, L., Zaragoza, B., Baeyens, A., Marodon, G., and Piag-
gio, E. (2013). Role of cytokines in thymus- versus peripherally derived-regula-
tory T cell differentiation and function. Front. Immunol. 4, 155.
Kono, K., Kawaida, H., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N.,
Omata, H., and Fujii, H. (2006). CD4(+)CD25high regulatory T cells increase
with tumor stage in patients with gastric and esophageal cancers. Cancer Im-
munol. Immunother. 55, 1064–1071.
Lahlou, H., Sanguin-Gendreau, V., Zuo, D., Cardiff, R.D., McLean, G.W.,
Frame, M.C., and Muller, W.J. (2007). Mammary epithelial-specific disruption
of the focal adhesion kinase blocks mammary tumor progression. Proc. Natl.
Acad. Sci. USA 104, 20302–20307.
Lim, S.T. (2013). Nuclear FAK: a newmode of gene regulation from cellular ad-
hesions. Mol. Cells 36, 1–6.
Lim, S.T., Chen, X.L., Lim, Y., Hanson, D.A., Vo, T.T., Howerton, K., Larocque,
N., Fisher, S.J., Schlaepfer, D.D., and Ilic, D. (2008). Nuclear FAK promotes cell
proliferation and survival through FERM-enhanced p53 degradation. Mol. Cell
29, 9–22.
Luo, M., Fan, H., Nagy, T., Wei, H., Wang, C., Liu, S., Wicha, M.S., and Guan,
J.L. (2009a). Mammary epithelial-specific ablation of the focal adhesion kinase
suppressesmammary tumorigenesis by affectingmammary cancer stem/pro-
genitor cells. Cancer Res. 69, 466–474.
Luo, S.W., Zhang, C., Zhang, B., Kim, C.H., Qiu, Y.Z., Du, Q.S., Mei, L., and
Xiong, W.C. (2009b). Regulation of heterochromatin remodelling and myoge-
nin expression during muscle differentiation by FAK interaction with MBD2.
EMBO J. 28, 2568–2582.
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008). Tumor-
induced tolerance and immune suppression by myeloid derived suppressor
cells. Immunol. Rev. 222, 162–179.
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T.,
Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010). Tumor-infiltrating NY-
ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in
human ovarian cancer. Proc. Natl. Acad. Sci. USA 107, 7875–7880.
McLean, G.W., Komiyama, N.H., Serrels, B., Asano, H., Reynolds, L., Conti, F.,
Hodivala-Dilke, K., Metzger, D., Chambon, P., Grant, S.G., and Frame, M.C.172 Cell 163, 160–173, September 24, 2015 ª2015 The Authors(2004). Specific deletion of focal adhesion kinase suppresses tumor formation
and blocks malignant progression. Genes Dev. 18, 2998–3003.
McLean, G.W., Carragher, N.O., Avizienyte, E., Evans, J., Brunton, V.G., and
Frame, M.C. (2005). The role of focal-adhesion kinase in cancer - a new ther-
apeutic opportunity. Nat. Rev. Cancer 5, 505–515.
Ondondo, B., Jones, E., Godkin, A., and Gallimore, A. (2013). Home sweet
home: the tumor microenvironment as a haven for regulatory T cells. Front. Im-
munol. 4, 197.
Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., andNakayama, E.
(1999). Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 re-
ceptor alpha) monoclonal antibody. Cancer Res. 59, 3128–3133.
Pardoll, D.M. (2012). The blockade of immune checkpoints in cancer immuno-
therapy. Nat. Rev. Cancer 12, 252–264.
Peggs, K.S., Quezada, S.A., Chambers, C.A., Korman, A.J., and Allison, J.P.
(2009). Blockade of CTLA-4 on both effector and regulatory T cell compart-
ments contributes to the antitumor activity of anti-CTLA-4 antibodies.
J. Exp. Med. 206, 1717–1725.
Provenzano, P.P., Inman, D.R., Eliceiri, K.W., Beggs, H.E., and Keely, P.J.
(2008). Mammary epithelial-specific disruption of focal adhesion kinase re-
tards tumor formation and metastasis in a transgenic mouse model of human
breast cancer. Am. J. Pathol. 173, 1551–1565.
Pylayeva, Y., Gillen, K.M., Gerald, W., Beggs, H.E., Reichardt, L.F., and Gian-
cotti, F.G. (2009). Ras- and PI3K-dependent breast tumorigenesis in mice and
humans requires focal adhesion kinase signaling. J. Clin. Invest. 119, 252–266.
Quezada, S.A., Peggs, K.S., Curran, M.A., and Allison, J.P. (2006). CTLA4
blockade and GM-CSF combination immunotherapy alters the intratumor bal-
ance of effector and regulatory T cells. J. Clin. Invest. 116, 1935–1945.
Roberts, W.G., Ung, E., Whalen, P., Cooper, B., Hulford, C., Autry, C., Richter,
D., Emerson, E., Lin, J., Kath, J., et al. (2008). Antitumor activity and pharma-
cology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res.
68, 1935–1944.
Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., and Ander-
son, A.C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaus-
tion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194.
Sakuishi, K., Ngiow, S.F., Sullivan, J.M., Teng, M.W., Kuchroo, V.K., Smyth,
M.J., and Anderson, A.C. (2013). TIM3(+)FOXP3(+) regulatory T cells are tis-
sue-specific promoters of T-cell dysfunction in cancer. OncoImmunology 2,
e23849.
Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., and Takabayashi, A. (2003).
CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:
possible involvement of regulatory T cells in disease progression. Cancer
98, 1089–1099.
Sato, E., Olson, S.H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth,
A.A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005). Intraepithelial
CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio
are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad.
Sci. USA 102, 18538–18543.
Serrels, A., McLeod, K., Canel, M., Kinnaird, A., Graham, K., Frame, M.C., and
Brunton, V.G. (2012). The role of focal adhesion kinase catalytic activity on the
proliferation and migration of squamous cell carcinoma cells. Int. J. Cancer
131, 287–297.
Shah, W., Yan, X., Jing, L., Zhou, Y., Chen, H., andWang, Y. (2011). A reversed
CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of
CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical
outcome in squamous cell carcinoma of the cervix. Cell. Mol. Immunol. 8,
59–66.
Shapiro, I.M., Kolev, V.N., Vidal, C.M., Kadariya, Y., Ring, J.E., Wright, Q.,
Weaver, D.T., Menges, C., Padval, M., McClatchey, A.I., et al. (2014). Merlin
deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Sci. Transl. Med. 6, 237ra68.
Shimizu, J., Yamazaki, S., and Sakaguchi, S. (1999). Induction of tumor immu-
nity by removing CD25+CD4+ T cells: a common basis between tumor immu-
nity and autoimmunity. J. Immunol. 163, 5211–5218.
Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K.,
Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. (2013). Fc-
dependent depletion of tumor-infiltrating regulatory T cells co-defines the effi-
cacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695–1710.
Slack-Davis, J.K., Hershey, E.D., Theodorescu, D., Frierson, H.F., and Par-
sons, J.T. (2009). Differential requirement for focal adhesion kinase signaling
in cancer progression in the transgenic adenocarcinoma of mouse prostate
model. Mol. Cancer Ther. 8, 2470–2477.
Stokes, J.B., Adair, S.J., Slack-Davis, J.K., Walters, D.M., Tilghman, R.W.,
Hershey, E.D., Lowrey, B., Thomas, K.S., Bouton, A.H., Hwang, R.F., et al.
(2011). Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth
and metastasis of pancreatic cancer concomitant with altering the tumor
microenvironment. Mol. Cancer Ther. 10, 2135–2145.
Tan, M.C., Goedegebuure, P.S., Belt, B.A., Flaherty, B., Sankpal, N., Gil-
landers, W.E., Eberlein, T.J., Hsieh, C.S., and Linehan, D.C. (2009). Disruption
of CCR5-dependent homing of regulatory T cells inhibits tumor growth in amu-
rine model of pancreatic cancer. J. Immunol. 182, 1746–1755.Thornton, A.M., Korty, P.E., Tran, D.Q., Wohlfert, E.A., Murray, P.E., Belkaid,
Y., and Shevach, E.M. (2010). Expression of Helios, an Ikaros transcription fac-
tor family member, differentiates thymic-derived from peripherally induced
Foxp3+ T regulatory cells. J. Immunol. 184, 3433–3441.
Turriziani, B., Garcia-Munoz, A., Pilkington, R., Raso, C., Kolch, W., and von
Kriegsheim, A. (2014). On-beads digestion in conjunctionwith data-dependent
mass spectrometry: a shortcut to quantitative and dynamic interaction prote-
omics. Biology (Basel) 3, 320–332.
Wherry, E.J. (2011). T cell exhaustion. Nat. Immunol. 12, 492–499.
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z.,
Nomura, T., and Sakaguchi, S. (2008). CTLA-4 control over Foxp3+ regulatory
T cell function. Science 322, 271–275.
Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin,
A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. (2013). Nivolu-
mab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133.Cell 163, 160–173, September 24, 2015 ª2015 The Authors 173
Supplemental Figures
Figure S1. T Cell FACS Analysis Post Antibody-Mediated T Cell Depletion, Related to Figure 1
(A) FACS analysis of spleen and thymus tissue from non-tumor-bearing animals 6 days after commencing antibody treatment. (B) FACS analysis of T cell
populations from spleen and thymus tissue from tumor-bearing animals at the end of T cell depletion studies in Figures 1C and 1D.
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Figure S2. T Cell FACS Gating Strategy, Related to Figures 2 and 7
(A) FACS gating strategy applied for identification of T cell sub-populations. E = effector, CM = central memory, and N = naive. (B) FMO (full antibody set minus
one) control samples used to determine correct gating for T cell sub-population identification.
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Figure S3. Macrophage FACS Gating Strategy, Related to Figure 3
(A) FACS gating strategy applied for identification of macrophage sub-populations. (B) FMO control samples used to determine correct gating for macrophage
sub-population identification.
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Figure S4. MDSC and Treg FACS Gating Strategy, Related to Figures 3 and 7
(A) FACS gating strategy applied for identification of MDSC sub-populations. M-MDSC – Monocytic Myeloid Derived Suppressor Cell; G-MDSC – Granulocytic
Myeloid Derived Suppressor Cell. (B) FMO control samples used to determine correct gating for MDSC sub-population identification. (C) FACS gating strategy
applied for identification of regulatory T cells (Treg).
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Figure S5. Tregs Infiltrating SCC FAK-WT Tumors Express the ThymicMarker Helios; Nuclear FAK Regulates Transcription of TGFb2, which
Contributes to Treg Expansion and Tumor Growth, Related to Figures 3 and 5
(A) FACS analysis of Helios expression in CD4+CD25+FOXP3+ SCC FAK-WT tumor-infiltrating Tregs and Tregs isolated from the thymus of tumor-bearing mice.
Control represents background signal from a sample stained with CD4, CD25, and FoxP3 conjugated antibodies but not Helios. Representative replicates are
shown in different colors for thymus and SCC FAK-WT samples. (B) qRT-PCR analysis of Tgfb2 gene expression knockdown in SCC cells. ****p < 0.0001 (Tukey-
corrected one-way ANOVA). (C) SCC FAK-WT shRNA-TGFb2 tumor growth in FVB mice. Blue dashed line indicates growth of SCC FAK-WT shRNA-TGFb2
tumors that had to be sacrificed due to ulceration at day 14. Red dashed line indicates growth of SCC FAK-WT shRNA-TGFb2 tumors that showed no ulceration.
Green solid line indicates the mean growth of all SCC FAK-WT shRNA-TGFb2 tumors up until cohort numbers were reduced due to ulceration. n = 6 tumors /
group. (D) FACS analysis of SCC FAK-WT shRNA-TGFb2 tumor infiltrating Tregs. ****p < 0.0001 (Tukey-corrected one-way ANOVA) (E) qRT-PCR analysis of
Tgfb2 gene expression in SCC FAK-NLS mutant cells. ***p < 0.001, ****p < 0.0001 (Tukey-corrected one-way ANOVA). Data are represented as mean ± SEM.
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Figure S6. Nuclear FAK Interactome in the Context of Ccl5 Transcription Factors, Related to Figure 6 and Table S1
(A) Interaction network analysis of proteins that bind FAK in the nucleus of SCC cells. Predicted Ccl5 transcription factors (TFs) (squares; bottom) and respective
TF binders (circles; top) enriched by at least two-fold in nuclear FAK immunoprecipitations (SCC FAK-WT over SCC FAK/ controls; p < 0.05) are shown. Ccl5
TFs not detected (ND) are shown as gray squares. TF complexes or groups are indicated; proteins are labeled with gene names for clarity. TF binders are aligned
above TF groups with which there are the greatest number of reported interactions. Overrepresented molecular functions determined by functional enrichment
analysis are displayed as a heat map (log10-transformed color scale) (inset). Displayed terms satisfy p < 0.01 (Benjamini–Hochberg-corrected hypergeometric
test) with > 5 proteins assigned per term. (B) Topological analysis of Ccl5 TF–associated proteins identified in the nuclear FAK interactome. Ccl5 TF binders were
clustered using the yFiles Organic algorithm implemented in Cytoscape. Topological parameters were computed using NetworkAnalyzer, excluding self-in-
teractions. Protein node size is proportional to the number of interaction partners in the network (degree); node color indicates betweenness centrality
(normalized number of shortest paths between proteins; a measure of the control a protein exerts over the interactions of other proteins in the network). Box-and-
whisker plots (inset) show the distributions of degree and betweenness centrality for Ccl5 TF–associated proteins that bind nuclear FAK compared to those that
were not enriched in nuclear FAK immunoprecipitations, indicating that FAK binders tend to havemore interactions and bemore central in the interaction network
than undetected Ccl5 TF–associated proteins. Plots display the median (line), interquartile range (box) and 1.5 3 interquartile range (whiskers) (n = 169 and 761
Ccl5 TF–associated proteins detected and not detected, respectively, with degreeR 1 based on physical or predicted interactions). ****p < 0.0001 (two-tailed
Mann–Whitney test).
See also Table S1.
Cell 163, 160–173, September 24, 2015 ª2015 The Authors S7
Figure S7. Analysis of FAK pY397 Phosphorylation in Tumors following Treatment with VS-4718, Related to Figure 7
Phosphorylation of FAK on Y397 was measured in protein lysates isolated from tumors following treatment with VS-4718 using ELISA. Tumors were removed
within 30 min of treatment. n = 5. Data are represented as mean ± SEM.
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  SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Animal Procedures 
All experiments involving animals were carried out in accordance with the UK Coordinating 
Committee on Cancer Research guidelines by approved protocol (Home Office Project 
Licence no. 60/4248). 
 
Generation of FAK Nuclear Localization Mutant (FAK-NLS) 
Point mutations were introduced into wild-type FAK (FAK-wt) at R177A, R178A, K190A, 
K191A, K216A, and K218A using site directed mutagenesis. Specifically, 20 ng of pWZL 
(Hygro) FAK-wt DNA template was mixed with 0.5 µM of each primer in PfuUltra Hotstart 
master mix (Stratagene) and subjected to PCR with cycle conditions as follows: 95°C (30 s), 
18 cycles; 95°C (30 s), 50°C (1 min), 68°C (12 min), final incubation 4°C (infinite). Following 
PCR, samples were incubated with 10 units of DpnI restriction enzyme at 37°C for 1 hour. 
The resulting product was transformed into TOP10 chemically competent bacteria (Life 
Technologies) and plated onto ampicillin agar plates. Colonies were selected and expanded 
in L broth containing ampicillin overnight, DNA was isolated using a QIAprep DNA miniprep 
kit (Qiagen), and mutational status was confirmed by sequencing. Three rounds of 
mutagenesis were required to generate FAK-NLS (R177A, R178A, K190A, K191A, K216A, 
K218A). Primer sequences were as follows:  
FAK R177A/R178A forward,  
CTAGGTTGCCTTGAAATCGCGGCATCCTACGGAGAGATGAG; 
FAK R177A/R178A reverse,  
CTCATCTCTCCGTAGGATGCCGCGATTTCAAGGCAACCTAG;  
FAK K190A/K191A forward,  
GAGGCAATGCATTAGAGGCGGCATCCAACTATGAAGTGCTAG;  
FAK K190A/K191A reverse,  
CTAGCACTTCATAGTTGGATGCCGCCTCTAATGCATTGCCTC;  
FAK K216A/K218A forward,  
GAAGAGTTTGCTAGATTCAGTGGCGGCCGCAACACTACGAAAATTAATC;  
FAK K216A/K218A reverse,  
GATTAATTTTCGTAGTGTTGCGGCCGCCACTGAATCTAGCAAACTCTTC.  
 
Cell Lines 
Isolation and generation of the FAK SCC cell model is described in detail in Serrels et al.	  
(Serrels et al., 2012). Briefly, SCCs were induced in K14CreER FAKflox/flox mice on the FVB 
background using the DMBA/TPA two-stage skin chemical carcinogenesis protocol and cells 
	  isolated. Following treatment with 4-hydroxytamoxifen, a FAK-null (FAK-/-) cell clone was 
isolated, and retroviral transduction was used to stably re-express FAK-wt, FAK kinase-dead 
(FAK-kd), and FAK-NLS. Briefly, Phoenix Ecotropic cells were transfected with pWZL 
(Hygro) FAK constructs using Lipofectamine 2000 (Life Technologies) according to 
manufacturer’s instructions. Twenty-four hours post-transfection, cell culture supernatant 
was removed, filtered through a 0.45-μm Millex-HA filter (Millipore), diluted at a 1:1 ratio in 
normal SCC cell culture medium, supplemented with 5 μg/ml polybrene, and added to SCC 
FAK-/- cells for 24 hours. A total of two rounds of infection were performed to generate each 
cell line. Cells were cultured at 37°C in Glasgow minimum essential medium (MEM) (Sigma-
Aldrich) supplemented with 2 mM L-glutamine, MEM vitamins, 1 mM sodium pyruvate (all 
Sigma-Aldrich), MEM amino acids, and 10% fetal bovine serum (FBS) (both Life 
Technologies), and maintained under selection using 0.25 mg/ml hygromycin. 
 
Western Blotting 
To prepare whole cell lysates, cells were washed twice in ice-cold phosphate-buffered saline 
(PBS) and lysed in RIPA buffer [50 mM Tris-HCl (pH 7.6), 150 mM sodium chloride, 1% 
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, cOmplete Ultra protease inhibitor 
cocktail (Roche), PhosSTOP phosphatase inhibitor cocktail (Roche)]. Cytoplasmic and 
nuclear extracts were prepared as described previously (Lim et al., 2008) and summarized 
below. Lysates were resolved by 4–15% Bis-Tris gel electrophoresis (Biorad), and proteins 
were transferred to nitrocellulose then blocked [5% bovine serum albumin in PBS–Tween 20 
(BSA/PBS-T)] and probed with either anti-Bcl2 (Cell Signaling Technology), anti-FAK 
(Becton Dickinson), anti-PARP (Cell Signaling Technology), anti-GAPDH (Cell Signaling 
Technology), rabbit anti-TAF9 (Abcam), or anti-tubulin (Becton Dickinson) primary antibodies 
(all 1:1000 in 5% BSA/PBS-T). Bound antibody was detected by incubation with anti-rabbit or 
anti-mouse DyLight800-conjugated secondary antibody or HRP-conjugated secondary 
antibody (Cell Signaling Technology) and visualized using a Licor Odyssey imaging system 
or a BioRad ChemiDoc MP Imaging System. 
 
Nuclear Fractionation 
SCC FAK-wt and SCC FAK-/- cells were grown on tissue culture dishes for 48 hours at 37°C 
prior to fractionation. Keratinocyte cultures were prepared from two-day-old FVB pups as 
described previously (McLean et al., 2004). Keratinocytes pooled from seven pups were 
grown on two tissue culture dishes for 72 hours at 37°C prior to fractionation. For subcellular 
fractionation, cells were washed twice with ice-cold PBS, scraped into ice-cold cyto buffer 
[10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.05% NP-40, 3 mM MgCl2, 1 mM EGTA, 
cOmplete Ultra protease inhibitor cocktail (Roche), PhosSTOP phosphatase inhibitor cocktail 
	  (Roche)] and incubated for 5 min on ice. Cytosolic supernatants were collected following 
centrifugation at 800 × g for 5 min at 4°C. Nuclear pellets were washed twice in cyto buffer, 
re-suspended in RIPA buffer and incubated for 15 min at 4°C. Nuclear supernatants were 
collected following centrifugation at 18,000 × g for 15 min at 4°C. For whole cell lysates, cells 
were washed twice with ice-cold PBS, scraped into RIPA buffer, and incubated for 15 min at 
4°C. Clarified supernatants were collected by centrifugation at 18,000 × g for 15 min at 4°C. 
Protein concentration was determined by BCA protein assay (Thermo Fisher Scientific), and 
Western blot analysis performed as described above. 
 
Subcutaneous Tumor Growth 
Cells were injected subcutaneously into both flanks of either CD-1 nude mice (0.25 × 106 
cells) or FVB mice (1 × 106 cells) and tumor growth measured twice-weekly using calipers. 
Animals were sacrificed when tumors reached maximum allowed size, or more commonly 
when signs of ulceration were evident. For studies involving treatment with VS-4718, drug 
was prepared in 0.5% carboxymethyl cellulose containing 0.1% Tween 80 (Sigma-Aldrich), 
and mice were treated at 75 mg/kg BID by oral gavage. Animals were visually monitored for 
signs of toxicity and weighed prior to each dose of VS-4718. No signs of toxicity were 
observed. Group sizes ranged from 3–5 mice, each bearing two tumors, and tumor volume 
was calculated in Excel (Microsoft) using the formula v = 4/3πr3. Statistics and graphs were 
calculated using Prism (GraphPad). 
 
Tumor Growth Following Re-challenge 
1 × 106 SCC FAK-/- cells were injected subcutaneously into the left flank of FVB mice and 
tumor growth measured twice-weekly as described above. Following tumor regression, mice 
were left for 7 days before being challenged with 1 × 106 SCC FAK-wt or FAK-/- cells 
injected subcutaneously into the right flank. Control groups were injected subcutaneously 
into both flanks at day 28 using mice that had not been pre-challenged with SCC FAK-/- 
cells. Tumor volume was calculated as described above. 
 
CD4+, CD8+, and CD25+ T-cell Depletion  
Anti-mouse CD4 (GK1.5, ATCC TIB-207) and CD8 (2.43, ATCC TIB-210) depleting 
antibodies were purified in-house from conditioned supernatant using a Melon Gel IgG 
purification kit or purchased from eBioscience (anti-CD4 clone GK1.5, anti-CD8 clone 53-
6.7). Rat IgG isotype control and anti-mouse CD25 (clone PC61.5) antibodies were 
purchased from eBioscience. T-cell depletion was achieved following intra-peritoneal (IP) 
injection of 150 μg of depleting antibody (same for all antibodies) into female age-matched 
FVB mice for 3 consecutive days, and maintained by further IP injection at 3-day intervals 
	  until the study was terminated. 1 × 106 SCC FAK-wt or FAK-/- cells were injected 
subcutaneously into both flanks 6 days after initial antibody treatment, and tumor growth was 
measured twice-weekly as described above. The extent of T-cell depletion was determined 
at the end of the study using FACS analysis of disaggregated spleen and thymus tissue 
(Figure S1). 
 
FACS Analysis of Immune Cell Populations 
Tumors established following injection of 1 × 106 SCC cells into both flanks of FVB mice 
were removed at day 7 into RPMI (Sigma-Aldrich) supplemented with 10% FBS (Life 
Technologies). Tumor tissue was mashed into a pulp using a scalpel and re-suspended in 
DMEM (Sigma-Aldrich) supplemented with 2 mg/ml collagenase D (Roche). Samples were 
incubated for 1 hour at 37°C, pelleted by centrifugation at 1600 rpm for 5 min at 4°C, re-
suspended in 5 ml of red blood cell lysis buffer (Pharm Lysis Buffer, Becton Dickinson) for 5 
min at 37°C, pelleted by centrifugation at 1600 rpm for 5 min at 4°C, re-suspended in PBS 
and passed through a 70-μm cell strainer. The resulting single cell suspension was pelleted 
by centrifugation at 1600 rpm for 5 min at 4°C and re-suspended in FACS buffer (PBS 
containing 1% FBS and 0.1% sodium azide). This step was repeated a total of three times. A 
sample of the suspension was counted using trypan blue exclusion and the remaining cell 
suspension pelleted by centrifugation at 1600 rpm for 5 min at 4°C and re-suspended in 
FACS buffer at a concentration of 1 × 106 viable cells/ml. One hundred microlitres of each 
sample were pipetted into each well of a 96-well plate and the plate centrifuged at 1600 rpm 
for 5 min at 4°C. Cell pellets were re-suspended in 50 μl of Fc block [1:200 dilution of Fc 
antibody (eBioscience) in FACS buffer] and incubated for 15 min at 4°C. Fifty microlitres of 
antibody mixture [1:200 dilution of antibodies (listed in Table S2) in FACS buffer] were added 
to each well and the samples incubated for 30 min in the dark at 4°C. The plate was then 
centrifuged at 1600 rpm for 5 min at 4°C and the cells re-suspended in FACS buffer and 
analyzed using a BD FACS Aria II. Regulatory T-cell staining was performed using a Treg 
staining kit (eBioscience). Staining of spleen and thymus tissue was performed as above. 
Data analysis was performed using FlowJo software. All antibodies were from eBioscience. 
For absolute counting, the same protocol as above was used, except tumors were weighed 
following surgical removal, and prior to FACS analysis samples were resuspended in varying 
volumes of FACS buffer (dependent on weight) containing CountBright Absolute Counting 
Beads (Life Technologies). Statistics and graphs were calculated using Prism (GraphPad). 
  
Gene Expression Profiling 
RNA was prepared from SCC FAK-wt and SCC FAK-/- cells using an RNAeasy kit (Qiagen) 
according to the manufacturer’s instructions. RNA was analysed using the GeneChip Mouse 
	  Genome 430 2.0 Array (Affymetrix). Gene expression data were analyzed using packages 
within Bioconductor (Gentleman et al., 2004) implemented in the R statistical programming 
language. The gene expression data were summarised from CEL files using Ensembl gene 
identifiers and normalized using the Robust Multi-array Average algorithm (Wu and Irizarry, 
2004) within the ‘affy’ package. The data discussed in this publication have been deposited 
in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO 
Series accession number GSE71662. Data for differentially expressed genes (p < 0.01) were 
median centered and subjected to unsupervised agglomerative hierarchical clustering on the 
basis of Euclidean distance computed with a complete-linkage matrix using Cluster 3.0 (C 
Clustering Library, version 1.37)	   (de Hoon et al., 2004). Clustering results were visualized 
using Java TreeView (version 1.1.1)	   (Saldanha, 2004). Functional enrichment analysis 
against the mouse genome background was performed using ToppGene (Chen et al., 2009). 
 
Quantitative RT2-PCR Array Analysis of Cytokine, Chemokine, and Chemokine 
Receptor Expression 
RNA prepared from SCC cells was analyzed using the mouse cytokine and chemokine RT2 
Profiler PCR Array (PAMM-150Z; Qiagen) and that from isolated Tregs (isolated using Treg 
isolation kit, 130-091-041; Miltenyi Biotech) was analyzed using the mouse chemokine and 
receptor array (PAMM-022Z; Qiagen) according to the manufacturer’s instructions. Relative 
gene expression (2−ΔCt) values were log transformed, median centered and subjected to 
hierarchical clustering as for microarray analysis. For interaction network analysis, an 
interactome of chemokine ligands and receptors was constructed using the IUPHAR/BPS 
Guide to Pharmacology database (Alexander et al., 2013; Pawson et al., 2014) and curated 
from the literature (Bachelerie et al., 2014), onto which expression data for detected genes 
were mapped and visualized using Cytoscape (version 3.0.2)	   (Shannon et al., 2003). In 
addition, expression of selected cytokine and chemokine genes was assessed by standard 
quantitative RT-PCR. TGFβ2-specific primers were purchased from Qiagen (catalog no. 
PPM02992A). Ccl5 primers used were: forward, CCCTCACCATCATCCTCACT; reverse, 
CCTTCGAGTGACAAACACGA. Cxcl10 primers used were: forward, 
CCCACGTGTTGAGATCATTG; reverse, CACTGGGTAAAGGGGAGTGA. B2M primers 
used were: forward, GGGAAGCCGAACATACTGAA; reverse, 
TGCTTAACTCTGCAGGCGTAT. Briefly, a reaction mix consisting of 10 μl SensiFAST 
SYBR Hi-ROX reagent (Bioline), 0.4 μl of 10 μM stock forward primer, 0.4 μl of 10 μM stock 
reverse primer, 4.4 μl water, and 4 μl of 20 ng/μl stock random hexamer primed cDNA was 
run on a Rotor-Gene qRT-PCR machine (Qiagen) using the following cycling conditions: 
94°C for 10 min; 40 cycles of 94°C for 10 s, 57°C for 20 s, 72°C for 20 s; and 72°C for 7 min. 
	  Analysis was performed using Rotor-Gene software, and expression relative to B2M was 
calculated using Excel (Microsoft). 
 
shRNA-mediated TGFβ2 and Ccl5 Knockdown 
To generate lentiviral particles, 2 × 106 HEK293FT cells were transfected with a mixture of 
10 μg shRNA (RMM4534-EG21808; GE Healthcare), 6.5 μg HIV, and 3 μg VSVG plasmid 
DNA using Lipofectamine 2000 as per manufacturer’s protocol. Twenty-four hours post-
transfection, medium was removed and filtered through a 0.45-μm Millex-AC filter (Millipore) 
and mixed at a 1:1 ratio with normal SCC growth medium. This mixture was supplemented 
with polybrene to a final concentration of 5 μg/ml and added to SCC cells for 24 hours. Cells 
were subject to two rounds of lentiviral infection prior to selection with puromycin at a final 
concentration of 2 μg/ml. All shRNA constructs used were part of the pLKO lentiviral TRC 
library (GE Healthcare). 
 
Preparation and Fractionation of Nuclei and Chromatin 
Nuclei were prepared as previously described (Gilbert et al., 2003) but with a reduced 
concentration (0.05%) of NP-40 in nuclei buffer B. Soluble chromatin was prepared as 
described previously (Gilbert et al., 2004) and fractionated on a 5-ml sucrose step gradient to 
separate soluble and chromatin-associated nuclear proteins. Essentially, the soluble 
chromatin was layered over 10% and 50% sucrose in TEP80 buffer [10 mM Tris-HCl (pH 
8.0), 1 mM EDTA, 80 mM NaCl, 100 μM PMSF] and centrifuged at 50,000 rpm for 1 h 50 
min in an MLS-50 rotor (Beckman). Five hundred–microlitre fractions were collected by 
upward displacement in a gradient fractionator (Teledyne ISCO). DNA was recovered from 
fractions using a PCR purification kit (Qiagen) and subjected to agarose (1.5%) gel 
electrophoresis. Protein was purified using TCA precipitation. Specifically, one volume of 
TCA stock solution was mixed with four volumes of protein solution, incubated at 4°C for 10 
min, and spun at 14,000 rpm for 5 min at 4°C. The supernatant was discarded, and the pellet 
was washed twice with ice-cold acetone and dried for 5 min at room temperature. Samples 
were analysed by SDS-PAGE and western blotted using anti-FAK (Cell Signalling 
Technologies), anti-HP1α (Millipore), and anti-histone H3 (Cell Signalling Technologies) 
antibodies. 
 
Proteomic Analysis of Nuclear FAK Protein Complexes 
Two milligrams of nuclear lysates were incubated with 10 μl agarose-conjugated anti-FAK 
antibody (clone 4.47; Merck Millipore) overnight at 4°C with rotation. Beads were washed 
twice with ice-cold RIPA buffer and twice with ice-cold PBS. Bead-bound complexes from 
biological triplicate experiments were subjected to on-bead proteolytic digestion, desalting 
	  and liquid chromatography–tandem mass spectrometry in technical duplicate as described 
previously (Turriziani et al., 2014). Mean label-free MS intensities were calculated from 
technical duplicate data acquisitions for each biological replicate. Peptide and protein false 
discovery rates were set to 1%. Proteins enriched from SCC FAK-wt nuclei by at least two-
fold over SCC FAK-/- control nuclei (p < 0.05) were considered specifically isolated by FAK 
immunoprecipitation. For interaction network analysis, Ccl5 transcription factors were 
extracted from the DECODE database (Qiagen) (most relevant transcription factors 
predicted to bind between 20 kb upstream and 10 kb downstream of the Ccl5 transcription 
starting site for human, mouse and rat) and used to seed a network of 1000 transcription 
factor–related proteins using the GeneMANIA plugin (version 2014-08-12-core; human 
interactions) in Cytoscape. Proteins specifically isolated in nuclear FAK protein complexes 
were mapped onto the interactome, and those with physical or predicted direct or indirect 
interactions with Ccl5 transcription factors were analyzed using the NetworkAnalyzer plugin 
(version 2.7) in Cytoscape. 
 
CD8 T-cell Fluorescent Immunohistochemistry 
SCC tumors were surgically removed 7 days post-implantation and snap-frozen in a cryovial 
by submersing in liquid nitrogen. Tumor sections were cut using a cryostat and stored at 
−80°C. Prior to staining, sections were moved to −20°C overnight. Slides were air-dried for 
30 min, fixed with ice-cold acetone (Sigma-Aldrich) for 10 min at room temperature, and 
washed three times for 5 min each in PBS. Tumor sections were outlined using a 
hydrophobic barrier pen (DAKO), then incubated with mouse background block for 1 h at 
room temperature. Samples were incubated with primary antibody [anti-mouse CD8α (clone 
53-6.7), rat IgG2a; R&D Systems; 1:100 dilution in 5% goat serum–2.5% BSA in PBS] for 1 h 
at room temperature, then washed three times with PBS-T, each for a period of 5 min, 
followed by three 5-min PBS washes. Samples were incubated with secondary antibody 
[Alexa Fluor 647 goat anti-rat IgG (H+L) (Life Technologies), 1:200 dilution] for 1 h at room 
temperature in the dark, then subjected to three 5-min washes with PBS-T, followed by one 
5-min wash with PBS and one wash with sterile water. Samples were mounted under a 
coverslip (Thermo Scientific) using ProLong Gold Antifade Mount containing DAPI (Life 
Technologies) and imaged using an Olympus FV1000 confocal microscope. Images were 
acquired using an UPLSAPO 20× lens. DAPI and Alexa Fluor 647 were imaged using 405-
nm and 635-nm excitation lasers. Three-dimensional image stitching was performed using 
the Olympus multi-site time-lapse module, with the final image comprising an 8 × 8 matrix 
with 20% overlap between adjacent images. Images were rendered using Imaris (Bitplane). 
  
	  SUPPLEMENTAL TABLES 
 
Table S2. Markers and Antibody Combinations Used to Define Immune Cell 
Populations, Related to Experimental Procedures 
(A) T-cell subsets for FACS analysis. (B) Macrophage subsets for FACS analysis. (C) MDSC 
subsets for FACS analysis. (D) Treg subsets for FACS analysis. 
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